The international BETH study for women with HER2-positive breast cancer is open for enrollment. The pivotal Phase III clinical trial is investigating the benefits of combining two blockbuster antibody drugs made by Swiss drug major Roche. The study will evaluate the anti-angiogenic Avastin (bevacizumab) and the targeted therapy Herceptin (trastuzumab) together with chemotherapy for patients with early-stage HER2-positive breast cancer.
"Trastuzumab is already the standard-of-care across all stages of HER2-positive breast cancer and has a proven survival benefit. Bevacizumab has been shown to be of benefit when given in combination with chemotherapy for the treatment of metastatic breast cancer," said Dennis Slamon, principal investigator of the Cancer International Research Group.
In BETH, patients will be randomized to a regimen of chemotherapy: either six cycles of docetaxel/carboplatin or three cycles of docetaxel, followed by three cycles of a regimen of 5-fluorouracil, epirubicin and cyclophosphamide plus trastuzumab with or without bevacizumab.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze